Vanguard National Trust
DGX icon

Vanguard National Trust’s Quest Diagnostics DGX Stock Holding History

Vanguard National Trust’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.2K Sell
166
-207
-55% -$40.6K ﹤0.01% 464
2026
Q1 		$73.1K Buy
+373
New +$72.5K ﹤0.01% 362

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Vanguard National Trust's DGX Position: Q2 2026 in Review

Vanguard National Trust reduced its Quest Diagnostics (DGX) stake by 55% in Q2 2026, selling an estimated $40.6K and leaving 166 shares worth $35.2K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Vanguard National Trust first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $73.1K in Q1 2026. 1,095 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Vanguard National Trust held 166 shares of Quest Diagnostics worth $35.2K as of Q2 2026.
  • Vanguard National Trust sold 207 Quest Diagnostics shares in Q2 2026, an estimated $40.6K.
  • Quest Diagnostics made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #464 holding.
  • Vanguard National Trust first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard National Trust's Quest Diagnostics position peaked at $73.1K in Q1 2026.
  • 1,095 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.